[HTML][HTML] Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance
DD Hill, JR Kramer, KR Chaffin, TC Mast… - Annals of …, 2023 - Elsevier
Abstract Introduction and Objectives In clinical trials, patients with hepatitis C virus (HCV)
genotype (GT) 1a infection and baseline resistance-associated substitutions (RASs) at …
genotype (GT) 1a infection and baseline resistance-associated substitutions (RASs) at …
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance.
DD Hill, JR Kramer, KR Chaffin, TC Mast… - Annals of …, 2023 - europepmc.org
Materials and methods This was a retrospective, observational analysis using electronic
health record abstraction. Patients with HCV GT1a infection and RASs at positions 28, 30 …
health record abstraction. Patients with HCV GT1a infection and RASs at positions 28, 30 …
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance
DD Hill, JR Kramer, KR Chaffin, TC Mast… - Annals of … - pubmed.ncbi.nlm.nih.gov
Introduction and objectives In clinical trials, patients with hepatitis C virus (HCV) genotype
(GT) 1a infection and baseline resistance-associated substitutions (RASs) at amino acid …
(GT) 1a infection and baseline resistance-associated substitutions (RASs) at amino acid …
Effectiveness of elbasvir/grazoprevir plus ribavirin for hepatitis C virus genotype 1a infection and baseline NS5A resistance.
DD Hill, JR Kramer, KR Chaffin… - … : Official Journal of …, 2023 - search.ebscohost.com
Abstract Introduction and Objectives: In clinical trials, patients with hepatitis C virus (HCV)
genotype (GT) 1a infection and baseline resistance-associated substitutions (RASs) at …
genotype (GT) 1a infection and baseline resistance-associated substitutions (RASs) at …